Dithranol


Concise Prescribing Info
Indications/Uses
Subacute and chronic psoriasis.
Dosage/Direction for Use
Adult : Topical Conventional treatment: As 0.1% oint/paste: Apply onto affected lesions for a few hr before washing off. May increase strength gradually as required from 0.5-1% and the duration of contact extended to overnight periods or longer. Short-contact therapy: As cream: Apply into lesions for up to 60 min/day before washing off. May increase strength gradually from 0.1-2%.
Dosage Details
Topical/Cutaneous
Subacute and chronic psoriasis
Adult: Conventional treatment: As 0.1% oint/paste: Apply onto the affected lesions for a few hr before washing off. May increase strength gradually as required from 0.5-1% and the duration of contact extended to overnight periods or longer. Short-contact therapy: As cream: Apply in a soft base to the lesions for up to 60 min daily before washing off. May increase strength gradually from 0.1-2%. Protect surrounding unaffected skin by applying white soft paraffin.
Child: Same as adult dose.
Special Patient Group
Patients w/ very fair skin: Conventional treatment: As 0.05% oint/paste: Apply onto the affected lesions for a few hr before washing off. May increase strength gradually as required from 0.5-1% and the duration of contact extended to overnight periods or longer.
Contraindications
Acute pustular psoriasis or inflamed skin.
Special Precautions
Patient w/ fair skin. Childn. Pregnancy and lactation.
Adverse Reactions
Burning sensation esp on perilesional skin, temporary staining of skin and hair; skin irritation and/or warmth feeling on application site.
Patient Counseling Information
Avoid eye contact and on sensitive skin area.
Overdosage
Symptoms: Burning and deep staining of the skin. Management: Rinse first w/ water only and then wash at a temp not exceeding 30°C.
Drug Interactions
May enhance the effect of photosensitising drugs. Propylene glycol-containing drugs may oxidise or inactivate dithranol. Withdrawal of long term steroids in psoriasis may cause rebound phenomenon.
Action
Description: Dithranol reduces the mitotic rate and proliferation of epidermal cells in psoriasis by inhibiting DNA replication, cellular respiration and key cellular enzymes.
Pharmacokinetics:
Absorption: Penetrates more into skin w/ impaired stratum corneum barrier than into intact skin. Reaches max concentration after 30-60 min contact time.
Distribution: Distributed in the horny layer of the skin (high concentrations of unchanged dithranol) and in the dermal layers (small amounts of unoxidised dithranol and high concentrations of dithranol dimer).
Metabolism: Unstable dithranol is oxidised to danthron dimer and further to insoluble polymerisation products.
Excretion: Small amounts of oxidised dithranol have been detected in urine.
Storage
Store between 15-30°C. Protect from excessive heat.
ATC Classification
D05AC01 - dithranol ; Belongs to the class of topical antracen derivative agent used in the treatment of psoriasis.
References
AFT Pharmaceuticals Ltd. Micanol data sheet 24 July 2007. Medsafe. http://www.medsafe.govt.nz/. Accessed 14/04/2016 .

Anon. Anthralin . Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 14/04/2016.

Buckingham R (ed). Dithranol. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 14/04/2016 .

Joint Formulary Committee. Dithranol (Anthralin). British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 14/04/2016 .

Disclaimer: This information is independently developed by MIMS based on Dithranol from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in